![](https://qtxasset.com/quartz/qcloud5/media/image/Viehbacher.jpg?VersionId=WQXs4eBmmuJBkenvY8T0vYw9KHCJuGs6)
Biogen CEO hails quartet of new launches as multiple sclerosis competition weighs on 2025 guidance
While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to be sitting well with investors, company leadership remains confident that a crop of new drugs can pick up the slack in the months …